NCT06470243Toboroz3. fázis
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jan. 22.
Rövid összefoglaló (regiszter, angolul)
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 528 (tervezett)
- Első benyújtás
- 2024. jún. 17.
- Kezdés
- 2024. nov. 27.
- Elsődleges befejezés
- 2029. jún. 30.
- Fő szponzor
- SWOG Cancer Research Network
- Betegségek
- Prosztatarák
- NCT-szám
- NCT06470243
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 528
- 2024. nov. 27. és az elsődleges befejezés (2029. jún. 30.) között
- 174 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Kiket keres a vizsgálat
- STEP 1 SCREENING REGISTRATION: NOTE: All participants must have biopsy tissue submitted to MD Anderson Cancer Center prior to randomization for alteration assessment. Participants must have determination of their AVPC-Molecular Pathologic Signature immunohistochemistry (MSIHC) status from central assessment by the MD Anderson Clinical Pathology Laboratory using Clinical Laboratory Improvement Act (CLIA) certified immunohistochemistry (IHC) assays for TP53, RB1 and PTEN. In addition, while not mandated, CLIA certified next generation sequencing (NGS) of tumor deoxyribonucleic acid (DNA) and/or circulating tumor derived DNA (ctDNA) assessment of AVPC-MS marker status will be collected from participants for whom it is available
- STEP 1 SCREENING REGISTRATION: Participants must have a histologically confirmed diagnosis of prostate cancer at the time of step 1 registration
- STEP 1 SCREENING REGISTRATION: Participants must have castrate-resistant prostate cancer and metastatic disease by bone scan and/or CT/MRI (i.e., soft tissue, visceral, lymph node)
- STEP 1 SCREENING REGISTRATION: Participants may have received any prior therapy, but one must be docetaxel or contain docetaxel in either the castrate-sensitive and/or castrate resistant disease state
- STEP 1 SCREENING REGISTRATION: Participants must be ≥ 18 years of age at the time of step 1 screening registration
- STEP 1 SCREENING REGISTRATION: Participants must have solid tumor biopsy material (formalin-fixed paraffin-embedded (FFPE) tissue blocks and/or 10 cut slides on four-micron thick unstained positive charged slides of FFPE tissue) available for submission for alterations in TP53, RB1 and PTEN by IHC using CLIA certified assays in the MD Anderson Clinical Pathology Laboratory. This specimen is required for central assessment of the AVPC-MSIHC regardless of whether the site has already locally evaluated the AVPC-MS status
- STEP 1 SCREENING REGISTRATION: Tumor samples submitted for analysis must have been collected within 12 months prior to step 1 screening registration. Samples from metastatic lesions collected in the castrate-resistant disease state are preferable but not mandatory. Samples obtained during the hormone-naive disease state are acceptable if collected within 12 months of step 1 screening registration. If more than one tumor sample exists, the sample obtained closest to the date of registration should be submitted to MDACC for analysis
- NOTE: Sites will receive an email from Southwest Oncology Group (SWOG) Statistics and Data Management Center containing participant results of Aggressive Variant Prostate Cancer Molecular Signature (AVPC-MS) assessment within 5-12 business days after tissue submission to MD Anderson Clinical Pathology Laboratory. The participant's AVPC-MS signature result (positive or negative) is required BEFORE randomization on to step 2. If sites receive a non-evaluable AVPC-MS signature result, SWOG Statistics and Data Management Center will provide instructions for resubmission
- STEP 1 SCREENING REGISTRATION: NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- STEP 1 SCREENING REGISTRATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. Documentation of informed consent via remote consent is allowed
- For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
- STEP 2 RANDOMIZATION: NOTE: Participants must be registered to step 2 randomization within 70 days after registration to step 1. Participants must plan to start protocol therapy no more than 14 days after step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have castrate levels of testosterone with a baseline level < 50ng/dL within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have evidence for metastatic prostate cancer by bone scan and/or CT/MRI (i.e., soft tissue, visceral, lymph node). Visceral and/or soft-tissue metastases must be ≥ 1.0 cm in diameter and lymph nodes must be > 1.5 cm diameter in the short axis. Scans must be obtained within 28 days prior to randomization
- NOTE: All disease must be assessed and documented on the baseline/pre-registration tumor assessment form
- STEP 2 RANDOMZIATION: Participants must have progressive disease (PD) in the opinion of the treating investigator according to any of the following criteria
- Progression in measurable disease (RECIST 1.1 criteria). Patient with measurable disease must have at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be at least 10 mm when measured by computed tomography (CT) [CT scan thickness no greater than 5 mm] or magnetic resonance imaging (MRI). Lymph nodes should be ≥ 15 mm in short axis. Previously irradiated lesions, primary prostate lesion and bone lesions will be considered non-measurable disease
- Progression in bone as evidenced by:
- Appearance of 2 or more new bone lesions on bone scan (BS). If equivocal, they must be confirmed by other imaging modalities (CT; MRI), and/or repeat BS > 4 weeks later
- Appearance of a new lytic lesion(s) and/or increasing size of an existing lesion by CT/MRI, since AVPC tumors may produce lytic bone lesions that are not detected on conventional bone scans
- Rising prostate-specific antigen (PSA) defined (Prostate Cancer Working Group 2 [PCWG2]) as at least two consecutive rises in PSA to be documented over a reference value (measure 1) taken at least one week apart. The first rising PSA (measure 2) should be taken at least 7 days after the reference value. A third confirmatory PSA measure is required (2nd beyond the reference level) to be greater than the second measure and it must be obtained at least 7 days after the 2nd measure. If this is not the case, a fourth PSA measure is required to be taken and be greater than the 2nd measure. In case of progression based on rising PSA only, the first rising PSA (measure 2) must be obtained within 6 months of initiation of androgen receptor (AR) targeted therapy (≤ 6 months)
- Clinical progression. Increasing symptoms unequivocally attributed to disease progression as judged by the treating physician
- STEP 2 RANDOMIZATION: Participants must not have received prior cabazitaxel or carboplatin
- STEP 2 RANDOMIZATION: Participants must not be receiving treatment on another therapeutic clinical trial at the time of randomization. Chemotherapies, bone targeting therapies, immunotherapies and clinical trial agents must be discontinued ≥ 21 days prior to randomization. Stereotactic radiation (SART) must be discontinued ≥ 3 days prior to randomization
- STEP 2 RANDOMIZATION: Participants must not be receiving radiation therapy or kyphoplasty-vertebroplasty within 14 days prior to randomization or major surgery (e.g., open abdominal, pelvic, thoracic, orthopedic or neurosurgery) within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must not have untreated fractures and/or cord compression
- STEP 2 RANDOMIZATION: Participants must not have symptomatic uncontrolled brain metastases. Properly treated brain metastases (i.e., with stereotactic radiation) within 14 days are allowed
- STEP 2 RANDOMIZATION: Participants must have Zubrod performance status of 0 - 2 within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have a complete medical history and physical exam within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Absolute neutrophil count ≥ 1.5 x 10\^3/uL (within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Platelets ≥ 100 x 10\^3/uL (unless clinical evidence of bone marrow infiltration by tumor in which case > 75 x 10\^3/uL are allowed) (within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Total bilirubin ≤ institutional upper limit of normal (ULN) with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome or if the participant has liver metastases and/or acute tumor associated illness < 4x ULN (within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × institutional ULN (or if participant has liver metastases and/or acute tumor-associated illness, ≤ 4x institutional ULN) (within 28 days prior to step 2 randomization)
- STEP 2 REGISTRATION: Participants must have a calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants with peripheral neuropathy must have ≤ grade 2 peripheral neuropathy (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) (within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Participants who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including vasectomy with testing showing no sperm in the semen
- STEP 2 RANDOMIZATION: Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen
- STEP 2 RANDOMIZATION: Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
- STEP 2 RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
Életkor a regiszterben: 18 év – - · Nem: csak férfiak · Egészséges önkénteseket nem fogad
Helyszínek (174)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Lehigh Valley Hospital-Cedar Crest | Allentown | Egyesült Államok | Toboroz |
| Community Hospital of Anaconda | Anaconda | Egyesült Államok | Toboroz |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Egyesült Államok | Toboroz |
| Saint Alphonsus Cancer Care Center-Baker City | Baker City | Egyesült Államok | Toboroz |
| Indu and Raj Soin Medical Center | Beavercreek | Egyesült Államok | Toboroz |
| Nebraska Medicine-Bellevue | Bellevue | Egyesült Államok | Toboroz |
| Lehigh Valley Hospital - Muhlenberg | Bethlehem | Egyesült Államok | Toboroz |
| Billings Clinic Cancer Center | Billings | Egyesült Államok | Toboroz |
| Illinois CancerCare-Bloomington | Bloomington | Egyesült Államok | Toboroz |
| Saint Elizabeth Boardman Hospital | Boardman | Egyesült Államok | Toboroz |
| Saint Alphonsus Cancer Care Center-Boise | Boise | Egyesült Államok | Toboroz |
| Bozeman Health Deaconess Hospital | Bozeman | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Egyesült Államok | Toboroz |
| Trinity Health Medical Center - Brighton | Brighton | Egyesült Államok | Toboroz |
| Minnesota Oncology - Burnsville | Burnsville | Egyesült Államok | Toboroz |
| Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Egyesült Államok | Toboroz |
| Cambridge Medical Center | Cambridge | Egyesült Államok | Toboroz |
| Illinois CancerCare-Canton | Canton | Egyesült Államok | Toboroz |
| Trinity Health Medical Center - Canton | Canton | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Egyesült Államok | Toboroz |
| Southeast Cancer Center | Cape Girardeau | Egyesült Államok | Toboroz |
| Saint Francis Medical Center | Cape Girardeau | Egyesült Államok | Toboroz |
| Memorial Hospital of Carbondale | Carbondale | Egyesült Államok | Toboroz |
| Caro Cancer Center | Caro | Egyesült Államok | Toboroz |
| SIH Cancer Institute | Carterville | Egyesült Államok | Toboroz |
| Illinois CancerCare-Carthage | Carthage | Egyesült Államok | Toboroz |
| Oncology Associates at Mercy Medical Center | Cedar Rapids | Egyesült Államok | Toboroz |
| Mercy Hospital | Cedar Rapids | Egyesült Államok | Toboroz |
| Dayton Physicians LLC-Miami Valley South | Centerville | Egyesült Államok | Toboroz |
| Centralia Oncology Clinic | Centralia | Egyesült Államok | Toboroz |
| Christiana Care Health System-Concord Health Center | Chadds Ford | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Egyesült Államok | Toboroz |
| Chelsea Hospital | Chelsea | Egyesült Államok | Toboroz |
| University of Illinois | Chicago | Egyesült Államok | Toboroz |
| Northwestern University | Chicago | Egyesült Államok | Toboroz |
| Oncology Hematology Care Inc-Kenwood | Cincinnati | Egyesült Államok | Toboroz |
| Newland Medical Associates-Clarkston | Clarkston | Egyesült Államok | Toboroz |
| Hematology Oncology Consultants-Clarkston | Clarkston | Egyesült Államok | Toboroz |
| Billings Clinic-Cody | Cody | Egyesült Államok | Toboroz |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Egyesült Államok | Toboroz |
| MD Anderson in The Woodlands | Conroe | Egyesült Államok | Toboroz |
| Mercy Hospital | Coon Rapids | Egyesült Államok | Toboroz |
| Dayton Physician LLC - Englewood | Dayton | Egyesült Államok | Toboroz |
| Decatur Memorial Hospital | Decatur | Egyesült Államok | Toboroz |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Egyesült Államok | Toboroz |
| Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Egyesült Államok | Toboroz |
| Henry Ford Health Saint John Hospital | Detroit | Egyesült Államok | Toboroz |
| Illinois CancerCare-Dixon | Dixon | Egyesült Államok | Toboroz |
| Great Lakes Cancer Management Specialists-Doctors Park | East China Township | Egyesült Államok | Toboroz |
| Pocono Medical Center | East Stroudsburg | Egyesült Államok | Toboroz |
| Fairview Southdale Hospital | Edina | Egyesült Államok | Toboroz |
| Crossroads Cancer Center | Effingham | Egyesült Államok | Toboroz |
| Christiana Care - Union Hospital | Elkton | Egyesült Államok | Toboroz |
| Illinois CancerCare-Eureka | Eureka | Egyesült Államok | Toboroz |
| Parkland Health Center - Farmington | Farmington | Egyesült Államok | Toboroz |
| Highlands Oncology Group - Fayetteville | Fayetteville | Egyesült Államok | Toboroz |
| Armes Family Cancer Center | Findlay | Egyesült Államok | Toboroz |
| Orion Cancer Care | Findlay | Egyesült Államok | Toboroz |
| Blanchard Valley Hospital | Findlay | Egyesült Államok | Toboroz |
| Hurley Medical Center | Flint | Egyesült Államok | Toboroz |
| Genesys Hurley Cancer Institute | Flint | Egyesült Államok | Toboroz |
| Genesee Cancer and Blood Disease Treatment Center | Flint | Egyesült Államok | Toboroz |
| Genesee Hematology Oncology PC | Flint | Egyesült Államok | Toboroz |
| Holy Cross Hospital | Fort Lauderdale | Egyesült Államok | Toboroz |
| Dayton Physicians LLC-Atrium | Franklin | Egyesült Államok | Toboroz |
| Western Illinois Cancer Treatment Center | Galesburg | Egyesült Államok | Toboroz |
| Illinois CancerCare-Galesburg | Galesburg | Egyesült Államok | Toboroz |
| Northwestern Medicine Cancer Center Delnor | Geneva | Egyesült Államok | Toboroz |
| The West Clinic - Wolf River | Germantown | Egyesült Államok | Toboroz |
| Northwestern Medicine Glenview Outpatient Center | Glenview | Egyesült Államok | Toboroz |
| Northwestern Medicine Grayslake Outpatient Center | Grayslake | Egyesült Államok | Toboroz |
| Great Falls Clinic | Great Falls | Egyesült Államok | Toboroz |
| Benefis Sletten Cancer Institute | Great Falls | Egyesült Államok | Toboroz |
| Wayne Hospital | Greenville | Egyesült Államok | Toboroz |
| Dayton Physicians LLC-Wayne | Greenville | Egyesült Államok | Toboroz |
| Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Grosse Pointe Woods | Egyesült Államok | Toboroz |
| Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods | Egyesült Államok | Toboroz |
| Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods | Egyesült Államok | Toboroz |
| Lehigh Valley Hospital-Hazleton | Hazleton | Egyesült Államok | Toboroz |
| MD Anderson West Houston | Houston | Egyesült Államok | Toboroz |
| Lyndon Baines Johnson General Hospital | Houston | Egyesült Államok | Toboroz |
| M D Anderson Cancer Center | Houston | Egyesült Államok | Toboroz |
| University of Mississippi Medical Center | Jackson | Egyesült Államok | Toboroz |
| Kalispell Regional Medical Center | Kalispell | Egyesült Államok | Toboroz |
| Greater Dayton Cancer Center | Kettering | Egyesült Államok | Toboroz |
| Kettering Medical Center | Kettering | Egyesült Államok | Toboroz |
| Illinois CancerCare-Kewanee Clinic | Kewanee | Egyesült Államok | Toboroz |
| Northwestern Medicine Lake Forest Hospital | Lake Forest | Egyesült Államok | Toboroz |
| University of Michigan Health - Sparrow Lansing | Lansing | Egyesült Államok | Toboroz |
| MD Anderson League City | League City | Egyesült Államok | Toboroz |
| Beebe Medical Center | Lewes | Egyesült Államok | Toboroz |
| Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Egyesült Államok | Toboroz |
| Tibor Rubin VA Medical Center | Long Beach | Egyesült Államok | Toboroz |
| Henry Ford Warren Hospital - Breast Macomb | Macomb | Egyesült Államok | Toboroz |
| Great Lakes Cancer Management Specialists-Macomb Medical Campus | Macomb | Egyesült Államok | Toboroz |
| Illinois CancerCare-Macomb | Macomb | Egyesült Államok | Toboroz |
| Fairview Clinics and Surgery Center Maple Grove | Maple Grove | Egyesült Államok | Toboroz |
| Saint John's Hospital - Healtheast | Maplewood | Egyesült Államok | Toboroz |
| Minnesota Oncology Hematology PA-Maplewood | Maplewood | Egyesült Államok | Toboroz |
| Saint Mary's Oncology/Hematology Associates of Marlette | Marlette | Egyesült Államok | Toboroz |
| Idaho Urologic Institute-Meridian | Meridian | Egyesült Államok | Toboroz |
| Beebe South Coastal Health Campus | Millville | Egyesült Államok | Toboroz |
| Health Partners Inc | Minneapolis | Egyesült Államok | Toboroz |
| Hennepin County Medical Center | Minneapolis | Egyesült Államok | Toboroz |
| Abbott-Northwestern Hospital | Minneapolis | Egyesült Államok | Toboroz |
| Community Medical Center | Missoula | Egyesült Államok | Toboroz |
| Monticello Cancer Center | Monticello | Egyesült Államok | Toboroz |
| Saint Alphonsus Cancer Care Center-Nampa | Nampa | Egyesült Államok | Toboroz |
| Christiana Care Health System-Christiana Hospital | Newark | Egyesült Államok | Toboroz |
| Medical Oncology Hematology Consultants PA | Newark | Egyesült Államok | Toboroz |
| Helen F Graham Cancer Center | Newark | Egyesült Államok | Toboroz |
| Cancer Center of Western Wisconsin | New Richmond | Egyesült Államok | Toboroz |
| New Ulm Medical Center | New Ulm | Egyesült Államok | Toboroz |
| HSHS Saint Elizabeth's Hospital | O'Fallon | Egyesült Államok | Toboroz |
| Cancer Care Center of O'Fallon | O'Fallon | Egyesült Államok | Toboroz |
| University of Oklahoma Health Sciences Center | Oklahoma City | Egyesült Államok | Toboroz |
| Nebraska Medicine-Village Pointe | Omaha | Egyesült Államok | Toboroz |
| University of Nebraska Medical Center | Omaha | Egyesült Államok | Toboroz |
| Saint Alphonsus Cancer Care Center-Ontario | Ontario | Egyesült Államok | Toboroz |
| Northwestern Medicine Orland Park | Orland Park | Egyesült Államok | Toboroz |
| Illinois CancerCare-Ottawa Clinic | Ottawa | Egyesült Államok | Toboroz |
| Illinois CancerCare-Pekin | Pekin | Egyesült Államok | Toboroz |
| Methodist Medical Center of Illinois | Peoria | Egyesült Államok | Toboroz |
| Illinois CancerCare-Peoria | Peoria | Egyesült Államok | Toboroz |
| Valley Radiation Oncology | Peru | Egyesült Államok | Toboroz |
| Illinois CancerCare-Peru | Peru | Egyesült Államok | Toboroz |
| Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac | Egyesült Államok | Toboroz |
| Newland Medical Associates-Pontiac | Pontiac | Egyesült Államok | Toboroz |
| Michigan Healthcare Professionals Pontiac | Pontiac | Egyesült Államok | Toboroz |
| Hope Cancer Center | Pontiac | Egyesült Államok | Toboroz |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls | Egyesült Államok | Toboroz |
| Illinois CancerCare-Princeton | Princeton | Egyesült Államok | Toboroz |
| Fairview Northland Medical Center | Princeton | Egyesült Államok | Toboroz |
| Beebe Health Campus | Rehoboth Beach | Egyesült Államok | Toboroz |
| Reid Health | Richmond | Egyesült Államok | Toboroz |
| VCU Massey Cancer Center at Stony Point | Richmond | Egyesült Államok | Toboroz |
| Virginia Commonwealth University/Massey Cancer Center | Richmond | Egyesült Államok | Toboroz |
| North Memorial Medical Health Center | Robbinsdale | Egyesült Államok | Toboroz |
| Highlands Oncology Group - Rogers | Rogers | Egyesült Államok | Toboroz |
| MyMichigan Medical Center Saginaw | Saginaw | Egyesült Államok | Toboroz |
| Oncology Hematology Associates of Saginaw Valley PC | Saginaw | Egyesült Államok | Toboroz |
| Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Egyesült Államok | Toboroz |
| Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Egyesült Államok | Toboroz |
| United Hospital | Saint Paul | Egyesült Államok | Toboroz |
| Regions Hospital | Saint Paul | Egyesült Államok | Toboroz |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint | Egyesült Államok | Toboroz |
| Saint Francis Regional Medical Center | Shakopee | Egyesült Államok | Toboroz |
| Welch Cancer Center | Sheridan | Egyesült Államok | Toboroz |
| Highlands Oncology Group | Springdale | Egyesült Államok | Toboroz |
| Southern Illinois University School of Medicine | Springfield | Egyesült Államok | Toboroz |
| Springfield Clinic | Springfield | Egyesült Államok | Toboroz |
| Memorial Medical Center | Springfield | Egyesült Államok | Toboroz |
| Lakeview Hospital | Stillwater | Egyesült Államok | Toboroz |
| Missouri Baptist Medical Center | St Louis | Egyesült Államok | Toboroz |
| MD Anderson in Sugar Land | Sugar Land | Egyesült Államok | Toboroz |
| Missouri Baptist Sullivan Hospital | Sullivan | Egyesült Államok | Toboroz |
| BJC Outpatient Center at Sunset Hills | Sunset Hills | Egyesült Államok | Toboroz |
| MyMichigan Medical Center Tawas | Tawas City | Egyesült Államok | Toboroz |
| Dayton Physicians LLC - Troy | Troy | Egyesült Államok | Toboroz |
| Ridgeview Medical Center | Waconia | Egyesült Államok | Toboroz |
| Saint Joseph Warren Hospital | Warren | Egyesült Államok | Toboroz |
| Great Lakes Cancer Management Specialists-Macomb Professional Building | Warren | Egyesült Államok | Toboroz |
| Henry Ford Madison Heights Hospital - Breast | Warren | Egyesült Államok | Toboroz |
| Saint John Macomb-Oakland Hospital | Warren | Egyesült Államok | Toboroz |
| Northwestern Medicine Cancer Center Warrenville | Warrenville | Egyesült Államok | Toboroz |
| Illinois CancerCare - Washington | Washington | Egyesült Államok | Toboroz |
| Saint Mary's Oncology/Hematology Associates of West Branch | West Branch | Egyesült Államok | Toboroz |
| Rice Memorial Hospital | Willmar | Egyesült Államok | Toboroz |
| Christiana Care Health System-Wilmington Hospital | Wilmington | Egyesült Államok | Toboroz |
| Minnesota Oncology Hematology PA-Woodbury | Woodbury | Egyesült Államok | Toboroz |
| Fairview Lakes Medical Center | Wyoming | Egyesült Államok | Toboroz |
| Saint Elizabeth Youngstown Hospital | Youngstown | Egyesült Államok | Toboroz |
| Huron Gastroenterology PC | Ypsilanti | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Egyesült Államok | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.